Press releases

Lynne Maquat, Ph.D., and Alexander Varshavsky, Ph.D., to receive 2024 Dr. Paul Janssen Award for their fundamental discoveries about regulated degradation of RNA and proteins.

No safety issues identified to date

Johnson & Johnson (NYSE: JNJ) announced today that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option will be presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session from October 15-18, 2024 in Savannah, Georgia.

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA® reduced risk of death by 23 percent at 24 months compared to enzalutamide

Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint